Co-Diagnostics opened lower at $0.24, compared with its previous close of $0.28. In the last trading session, the stock traded between $0.24 and $0.26. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Co-Diagnostics is now worth
$ 0.10
Resulting in a loss of
$ 99.90 (99.90%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.01 (-4.61%)
Day High
$0.26
Day Low
$0.24
Day Open
$0.24
Prev Close
$0.28
Volume
11,58,972
1W Return
-27.40%
1M Return
-78.88%
3M Return
-82.08%
6M Return
-86.05%
1Y Return
-97.76%
Market Cap ($ Mn)
3
PE Ratio
-
PB Ratio
0.47
PEG Ratio
-
ROE
-115.28%
ROCE
-115.64%
EPS (TTM)
$-1.29
1 Week
-27.40%
1 Month
-78.88%
3 Months
-82.08%
6 Months
-86.05%
9 Months
-88.72%
Co-Diagnostics offers up to 39.6M shares for resale in loan deal
Co-Diagnostics Inc. filed for the resale of up to 39.6 million shares. The offering is linked to a $3.1 million convertible loan deal. Shares are being sold by the lender, not newly issued by the company.
8 days agoCo-Diagnostics CFO Brian Brown departs; Daniel Bohrer appointed
Brian Brown departs Co-Diagnostics on September 2, 2026. Daniel Bohrer appointed Principal Financial Officer. Brown served as principal accounting officer until departure.
2mo agoCo-Diagnostics Q2 Results: Net loss narrows to $6.3 million
Co-Diagnostics Inc. reported a Q2 2026 net loss of $6.3 million, improved from $7.7 million year-over-year, driven by reduced operating expenses. Revenue remained flat at $166,000. Cash reserves fell to $3.6 million from $11.9 million. The company submitted FDA applications for its Flu/RSV assay and advanced its TB program in India.
3mo agoCo-Diagnostics files FDA 510(k) for Co-Dx PCR Flu A/B & RSV test
Co-Diagnostics has submitted a Dual 510(k) and CLIA Waiver application to the FDA for its Co-Dx PCR Flu A/B & RSV test, targeting point-of-care settings. The filing is supported by extensive validation data, including a clinical study of over 1,400 patients and an analytical program comprising more than 10,000 test runs across 27 studies.
3mo agoCo-Diagnostics ships 200 Ebola test kits to India for pandemic readiness
Co-Diagnostics Inc. reported that its Indian JV, CoSara Diagnostics, shipped 200 SARAGENE Bundibugyo Virus Test kits to C-CAMP in India. This follows a successful proof-of-concept for an extraction-free Ebola test on the Co-Dx PCR Pro platform. The company is also developing a pan-Ebola assay to detect multiple species simultaneously.
3mo agoCo-Diagnostics amends equity distribution agreement with Maxim Group for $7.90M stock sale
Co-Diagnostics filed an amendment to its equity distribution agreement with Maxim Group. The updated terms allow the company to offer and sell up to $7.90 million of common stock through various methods, including at-the-market transactions.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Co-Diagnostics is now worth
$ 0.10
Resulting in a loss of
$ 99.90 (99.90%)
Note: Past profits do not guarantee future returns.
